Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 4,000
Out of 5,112 analysts
59
Total ratings
33.33%
Success rate
-12.48%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.89 | +5.82% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.99 | +28.76% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.61 | +334.78% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $11.45 | +57.21% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.15 | -13.04% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $6.14 | +225.73% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $10.07 | +168.12% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $5.63 | +130.91% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.79 | +141.80% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $510.94 | -35.41% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $59.82 | -3.04% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $82.28 | -69.62% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $14.24 | +244.10% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.18 | +88.68% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $33.68 | -43.59% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $65.24 | +83.94% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $10.63 | +370.37% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $13.73 | +191.33% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.89
Upside: +5.82%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.99
Upside: +28.76%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.61
Upside: +334.78%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $11.45
Upside: +57.21%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.15
Upside: -13.04%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.14
Upside: +225.73%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.07
Upside: +168.12%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $5.63
Upside: +130.91%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.79
Upside: +141.80%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $510.94
Upside: -35.41%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $59.82
Upside: -3.04%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $82.28
Upside: -69.62%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $14.24
Upside: +244.10%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.18
Upside: +88.68%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $33.68
Upside: -43.59%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $65.24
Upside: +83.94%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $10.63
Upside: +370.37%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $13.73
Upside: +191.33%